尼可地尔联合曲美他嗪在不稳定心绞痛患者中应用的临床研究

Clinical Study of Nicorandil Combined with Trimetazidine in Patients with Unstable Angina Pectoris

目的观察尼可地尔联合曲美他嗪治疗不稳定心绞痛应用中的临床疗效。方法选择2017年9月～2018年9月就诊于天津市第三中心医院诊断为心绞痛的患者共156例。随机分为观察组与对照组,各78例。对照组给予常规抗心绞痛药物治疗,观察组在对照组基础上加用尼可地尔,同时给予曲美他嗪缓释片治疗,观察两组患者心电图变化、临床疗效及不良反应情况。结果观察组心绞痛改善总有效率为92.31%,高于对照组的78.21%,差异有统计学意义(P<0.05);观察组心电图缺血情况改善总有效率为85.90%,高于对照组的64.10%,差异有统计学意义(P<0.05);观察组不良反应发生率为21.79%,低于对照组的24.36%,但差异无统计学意义(P>0.05)。结论尼可地尔联合曲美他嗪治疗不稳定心绞痛临床疗效显著,可有效改善患者心肌缺血症状,且不增加不良反应,安全性好。

Objective To observe the clinical efficacy of nicorandil combined with trimetazidine in the treatment of unstable angina pectoris.Methods A total of 156 patients with angina pectoris diagnosed in the Third Central Hospital of Tianjin from September 2017 to September 2018 were randomly divided into observation group and control group, with 78 cases in each group. The control group was given conventional anti-angina drug treatment. The observation group was treated with nicorandil and the trimetazidine sustained-release tablets. The changes of electrocardiogram, clinical efficacy and adverse reactions were observed.Results The total effective rate of angina pectoris improvement in the observation group was 92.31%, which was higher than 78.21% in the control group,the difference was statistically significant (P<0.05).The total effective rate of electrocardiogram ischemia improved in the observation group was 85.90%, which was higher than that of the control group 64.10%, the difference was statistically significant (P<0.05);the incidence of adverse reactions in the observation group was 21.79%, which was lower than 24.36% in the control group, but the difference was not statistically significant (P>0.05). Conclusion Nicorandil combined with trimetazidine is effective in the treatment of unstable angina pectoris. It can effectively improve the symptoms of myocardial ischemia in patients without increasing adverse reactions and safety.